Moderna, Inc. (MRNA) 今日盘中大涨5.53%，股价报56.285美元，引发市场广泛关注。
消息面上，多家机构近期同步上调了Moderna的目标价，为股价上涨提供了短期催化。其中，瑞银将目标价从45美元上调至50美元，维持中性评级；美银全球研究将目标价从38美元上调至40美元。同时，公司第五款产品Mflusiva即将于8月5日迎来美国食品药品监督管理局（FDA）的PDUFA审批关键节点，市场对其获批的预期持续升温。此前，公司季节性流感疫苗候选产品mRNA-1010已获得FDA咨询委员会9票赞成、0票反对的一致支持，进一步强化了市场信心。
此外，公司基本面亦有所改善。Moderna第二季度每股亏损为-1.97美元，优于市场预期的-2.01至-2.10美元，同期营收1.45亿美元也超出预期，为股价提供了坚实支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.